© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
A panel of experts explore the clinical and economic burden of vitiligo, review treatment paradigms and standard of care therapies, and discuss unmet needs and future directions for treatment of vitiligo.
August 19th 2022
A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.
David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.
August 26th 2022
Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.
David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.
September 2nd 2022
Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.
Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.
September 9th 2022
The panel of experts address the economic burden of vitiligo from payer and provider perspectives.
Key opinion leaders discuss how diagnosing vitiligo can lead to myriad treatment options.
September 16th 2022
A variety of treatment options for vitiligo are explored by Drs Dunn, Rosmarin, and King.
Navigating payer and provider considerations to ensure optimal care management for vitiligo.